Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Core Insights - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with upcoming participation in key investment conferences [1][2][4] - Dr. Shankar Musunuri, the CEO, will engage in discussions aimed at expanding the company's visibility and investor relations in the biotech sector [2][4] Conference Details - Dr. Musunuri will participate in the H.C. Wainwright 27 Annual Global Investment Conference from September 8-10, 2025, in New York, with a fireside chat scheduled for September 8 at 5 p.m. ET [3] - The company will also be featured in a panel discussion titled "The FDA Gauntlet: Strategies for a Successful Run at Approval" during Biotech on Tap 2025, taking place from September 24-26, 2025, in Munich, with the panel set for September 25 at 3:30 p.m. CET [3] Company Overview - Ocugen's modifier gene therapy platform aims to address significant unmet medical needs for large patient populations suffering from inherited retinal diseases and other blindness conditions, including retinitis pigmentosa and geographic atrophy [4] - The company's approach is gene-agnostic, targeting complex diseases caused by imbalances in multiple gene networks, differentiating it from traditional gene therapies [4]